Anne P Beigneux1, Kazuya Miyashita1, Michael Ploug1, Dirk J Blom1, Masumi Ai1, MacRae F Linton1, Weerapan Khovidhunkit1, Robert Dufour1, Abhimanyu Garg1, Maureen A McMahon1, Clive R Pullinger1, Norma P Sandoval1, Xuchen Hu1, Christopher M Allan1, Mikael Larsson1, Tetsuo Machida1, Masami Murakami1, Karen Reue1, Peter Tontonoz1, Ira J Goldberg1, Philippe Moulin1, Sybil Charrière1, Loren G Fong1, Katsuyuki Nakajima1, Stephen G Young1. 1. From the Departments of Medicine (A.P.B., M.A.M., N.P.S., X.H., C.M.A., M.L., L.G.F., S.G.Y.), Rheumatology (M.A.M.), Human Genetics (K.R., S.G.Y.), and Pathology and Laboratory Medicine (P.T.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, and the Cardiovascular Research Institute and Department of Physiological Nursing, University of California, San Francisco, San Francisco (C.R.P.); the Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi (K.M., T.M., M.M., K.N.), and the Department of Insured Medical Care Management, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo (M.A.) - both in Japan; the Finsen Laboratory, Rigshospitalet, Copenhagen (M.P.); the Department of Medicine, University of Cape Town, Cape Town, South Africa (D.J.B.); the Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville (M.F.L.); the Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross Society, Bangkok, Thailand (W.K.); Clinique de Prévention Cardiovasculaire, Institut de Recherches Cliniques de Montréal, University of Montreal, Montreal (R.D.); the Department of Medicine, University of Texas Southwestern Medical Center, Dallas (A.G.); the Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, New York University School of Medicine, New York (I.J.G.); and Fédération d'Endocrinologie, Groupement Hospitalier Est, Hospices Civils de Lyon, INSERM UMR-1060 Carmen, Université de Lyon, Lyon, France (P.M., S.C.).
Abstract
BACKGROUND: A protein that is expressed on capillary endothelial cells, called GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1), binds lipoprotein lipase and shuttles it to its site of action in the capillary lumen. A deficiency in GPIHBP1 prevents lipoprotein lipase from reaching the capillary lumen. Patients with GPIHBP1 deficiency have low plasma levels of lipoprotein lipase, impaired intravascular hydrolysis of triglycerides, and severe hypertriglyceridemia (chylomicronemia). During the characterization of a monoclonal antibody-based immunoassay for GPIHBP1, we encountered two plasma samples (both from patients with chylomicronemia) that contained an interfering substance that made it impossible to measure GPIHBP1. That finding raised the possibility that those samples might contain GPIHBP1 autoantibodies. METHODS: Using a combination of immunoassays, Western blot analyses, and immunocytochemical studies, we tested the two plasma samples (as well as samples from other patients with chylomicronemia) for the presence of GPIHBP1 autoantibodies. We also tested the ability of GPIHBP1 autoantibodies to block the binding of lipoprotein lipase to GPIHBP1. RESULTS: We identified GPIHBP1 autoantibodies in six patients with chylomicronemia and found that these autoantibodies blocked the binding of lipoprotein lipase to GPIHBP1. As in patients with GPIHBP1 deficiency, those with GPIHBP1 autoantibodies had low plasma levels of lipoprotein lipase. Three of the six patients had systemic lupus erythematosus. One of these patients who had GPIHBP1 autoantibodies delivered a baby with plasma containing maternal GPIHBP1 autoantibodies; the infant had severe but transient chylomicronemia. Two of the patients with chylomicronemia and GPIHBP1 autoantibodies had a response to treatment with immunosuppressive agents. CONCLUSIONS: In six patients with chylomicronemia, GPIHBP1 autoantibodies blocked the ability of GPIHBP1 to bind and transport lipoprotein lipase, thereby interfering with lipoprotein lipase-mediated processing of triglyceride-rich lipoproteins and causing severe hypertriglyceridemia. (Funded by the National Heart, Lung, and Blood Institute and the Leducq Foundation.).
BACKGROUND: A protein that is expressed on capillary endothelial cells, called GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1), binds lipoprotein lipase and shuttles it to its site of action in the capillary lumen. A deficiency in GPIHBP1 prevents lipoprotein lipase from reaching the capillary lumen. Patients with GPIHBP1 deficiency have low plasma levels of lipoprotein lipase, impaired intravascular hydrolysis of triglycerides, and severe hypertriglyceridemia (chylomicronemia). During the characterization of a monoclonal antibody-based immunoassay for GPIHBP1, we encountered two plasma samples (both from patients with chylomicronemia) that contained an interfering substance that made it impossible to measure GPIHBP1. That finding raised the possibility that those samples might contain GPIHBP1 autoantibodies. METHODS: Using a combination of immunoassays, Western blot analyses, and immunocytochemical studies, we tested the two plasma samples (as well as samples from other patients with chylomicronemia) for the presence of GPIHBP1 autoantibodies. We also tested the ability of GPIHBP1 autoantibodies to block the binding of lipoprotein lipase to GPIHBP1. RESULTS: We identified GPIHBP1 autoantibodies in six patients with chylomicronemia and found that these autoantibodies blocked the binding of lipoprotein lipase to GPIHBP1. As in patients with GPIHBP1 deficiency, those with GPIHBP1 autoantibodies had low plasma levels of lipoprotein lipase. Three of the six patients had systemic lupus erythematosus. One of these patients who had GPIHBP1 autoantibodies delivered a baby with plasma containing maternal GPIHBP1 autoantibodies; the infant had severe but transient chylomicronemia. Two of the patients with chylomicronemia and GPIHBP1 autoantibodies had a response to treatment with immunosuppressive agents. CONCLUSIONS: In six patients with chylomicronemia, GPIHBP1 autoantibodies blocked the ability of GPIHBP1 to bind and transport lipoprotein lipase, thereby interfering with lipoprotein lipase-mediated processing of triglyceride-rich lipoproteins and causing severe hypertriglyceridemia. (Funded by the National Heart, Lung, and Blood Institute and the Leducq Foundation.).
Authors: Xuchen Hu; Mark W Sleeman; Kazuya Miyashita; MacRae F Linton; Christopher M Allan; Cuiwen He; Mikael Larsson; Yiping Tu; Norma P Sandoval; Rachel S Jung; Alaleh Mapar; Tetsuo Machida; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux Journal: J Lipid Res Date: 2016-11-15 Impact factor: 5.922
Authors: Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel Journal: Transfusion Date: 2016-04-04 Impact factor: 3.157
Authors: Anne P Beigneux; Loren G Fong; André Bensadoun; Brandon S J Davies; Monika Oberer; Henrik Gårdsvoll; Michael Ploug; Stephen G Young Journal: Circ Res Date: 2014-11-11 Impact factor: 17.367
Authors: Remco Franssen; Stephen G Young; Frank Peelman; Jozef Hertecant; Jeroen A Sierts; Alinda W M Schimmel; André Bensadoun; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Anne P Beigneux Journal: Circ Cardiovasc Genet Date: 2010-02-02
Authors: Lise Schwarz-Lauer; Pavel N Pichurin; Chun-Rong Chen; Yuji Nagayama; Charmaine Paras; John C Morris; Basil Rapoport; Sandra M McLachlan Journal: Endocrinology Date: 2003-05 Impact factor: 4.736
Authors: Jonathan J Rios; Savitha Shastry; Juan Jasso; Natalie Hauser; Abhimanyu Garg; André Bensadoun; Jonathan C Cohen; Helen H Hobbs Journal: J Inherit Metab Dis Date: 2011-10-19 Impact factor: 4.982
Authors: Jun Eguchi; Kazuya Miyashita; Isamu Fukamachi; Katsuyuki Nakajima; Masami Murakami; Yuko Kawahara; Toru Yamashita; Yasuyuki Ohta; Koji Abe; Atsuko Nakatsuka; Mai Mino; Satoru Takase; Hiroaki Okazaki; Robert A Hegele; Michael Ploug; Xuchen Hu; Jun Wada; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2018-10-24 Impact factor: 4.766
Authors: Katrine Z Leth-Espensen; Kristian K Kristensen; Anni Kumari; Anne-Marie L Winther; Stephen G Young; Thomas J D Jørgensen; Michael Ploug Journal: Proc Natl Acad Sci U S A Date: 2021-03-23 Impact factor: 11.205
Authors: Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2017-06-13 Impact factor: 4.766
Authors: Kristian K Kristensen; Katrine Zinck Leth-Espensen; Haydyn D T Mertens; Gabriel Birrane; Muthuraman Meiyappan; Gunilla Olivecrona; Thomas J D Jørgensen; Stephen G Young; Michael Ploug Journal: Proc Natl Acad Sci U S A Date: 2020-02-07 Impact factor: 11.205
Authors: Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux Journal: J Lipid Res Date: 2020-09-18 Impact factor: 5.922
Authors: Antwi-Boasiako Oteng; Philip M M Ruppert; Lily Boutens; Wieneke Dijk; Xanthe A M H van Dierendonck; Gunilla Olivecrona; Rinke Stienstra; Sander Kersten Journal: J Lipid Res Date: 2019-08-13 Impact factor: 5.922